US 11,110,185 B2 · Combination formulation

Abstract

The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.

Claims28

Dependent claims

A pharmaceutical composition comprising:

(i) a first active pharmaceutical ingredient (API) having greater than 10% hepatocellular uptake and biliary excretion, wherein the first API is gadoexetate;
and,
(ii) a second API that is a metal chelate comprising a chelant or a derivative thereof and a paramagnetic metal ion, said second API having renal excretion and a lower level of hepatocellular uptake and biliary excretion than the first API;
(iii) a biocompatible carrier comprising excess free chelant in a form suitable for mammalian administration;
wherein the ratio of said first API to said second API is from 1:10 to 4:1.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/768,831Filed 30 Nov 2016 · us provisional application

Priority

30 Nov 2015

Published

US 2018/0303960 A125 Oct 2018

Granted

7 Sep 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

A61K 49/105
The complex-forming compound being acyclic, e.g. DTPA: the metal complex being Gd-DTPA
A61K 49/101
Organic compounds: the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
A61K 49/108
The complex-forming compound being cyclic, e.g. DOTA: the metal complex being Gd-DOTA
A61K 2123/00
Preparations for testing in vivo

Combination formulation

Life of this patent

Combination formulation

Life of this patent

Abstract

Claims28